Methods of treating Parkinson's disease
AssigneeAbbVie Inc.
InventorsBrian P. Enright, Ye Huang, Philip R. Kym, Yanbin Lao, Xiaochun Lou, Sean E. Mackey, Peter T. Mayer, Christopher P. Miller, Valentino J. Stella, Eric A. Voight
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to (a) carbidopa prodrugs, (b) pharmaceutical combinations and compositions comprising a carbidopa prodrug and/or an L-dopa prodrug, and (c) methods of treating Parkinson's disease and associated conditions comprising administering a carbidopa prodrug and an L-dopa prodrug to a subject with Parkinson's disease.
Claims17
A method of delivering dopamine to a Parkinson's disease patient in a pharmacokinetically-consistent manner comprising, continuously subcutaneously administering an aqueous pharmaceutical formulation to the patient, the formulation comprising:
- (a) at least about 5 mg/mL of a compound comprising levodopa,
- (b) carbidopa, or a pharmaceutically acceptable salt thereof, and
- (c) an aqueous carrier,
- wherein the method is sufficient to achieve a steady state levodopa plasma level of about 1000 ng/ml to about 5000 ng/ml in the patient for at least 8 hours without co-administration of a catechol-0-methyl transferase inhibitor.
Dependencies are inferred from the claim text.